Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
BMC Cancer. 2023 Jun 5;23(1):509. doi: 10.1186/s12885-023-10865-8.
E2F1 has been confirmed to be highly expressed in a variety of cancers. To better understand the prognostic value of E2F1 in cancer patients, this study was conducted to comprehensively evaluate the prognostic value of E2F1 in cancer according to published data.
PubMed, Web of Science and CNKI database were searched until May 31, 2022 by using key words to retrieve the published essays on the role of E2F1 expression in the prognostic value of cancer. The essays were identified according to the inclusion and exclusion criteria. The pooled result of hazard ratio and 95% confidence interval was calculated with Stata17.0 software.
A total of 17 articles were included in this study involved in 4481 cancer patients. The pooled results showed that higher E2F1 expression was significantly correlated with unfavorable overall survival (HR = 1.10, I = 95.3%, *P = 0.000) and disease-free survival (HR = 1.41, I = 95.2%, *P = 0.000) of cancer patients. Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, and for DFS, HR = 0.91; or < 150: for OS, HR = 1.93, and for DFS, HR = 4.39), ethnicity (Asian: for OS, HR = 1.65, and for DFS, HR = 1.08; or not Asian: HR = 3.55, and for DFS, HR = 2.87), the data from database (clinical: for OS, HR = 1.24, and for DFS, HR = 1.40; or database: for OS, HR = 2.29, and for DFS, HR = 3.09), paper published year (after 2014: for OS, HR = 1.90;and for DFS,HR = 1.87; or before 2014: for OS, HR = 1.40, and for DFS, HR = 1.22); cancer type (female specific cancer: for OS, HR = 1.41, and for DFS, HR = 0.64; or non-gender specific cancers: for OS, HR = 2.00, and for DFS, HR = 2.95). In addition, according to the database data, we also found that higher E2F1 expression level would lead to worse prognosis of patients, and the results were consistent with the statistical analysis results in the paper.
E2F1 could be served as a prognostic biomarker in cancer patients and higher levels of in cancer patients could predict shorter overall survival and disease-free survival.
E2F1 已被证实在多种癌症中高度表达。为了更好地了解 E2F1 在癌症患者中的预后价值，本研究通过检索已发表的关于 E2F1 表达在癌症预后价值中的作用的文章，综合评估 E2F1 在癌症中的预后价值。
检索PubMed、Web of Science 和中国知网（CNKI）数据库，使用关键词检索截至 2022 年 5 月 31 日发表的关于 E2F1 表达在癌症预后价值中作用的文章。根据纳入和排除标准筛选文章。使用 Stata17.0 软件计算风险比和 95%置信区间的合并结果。
本研究共纳入 17 项研究，涉及 4481 例癌症患者。合并结果显示，E2F1 表达水平升高与癌症患者的总生存期（HR=1.10，I=95.3%，*P=0.000）和无病生存期（HR=1.41，I=95.2%，*P=0.000）不良显著相关。这种显著的相关性在亚组分析中也得到了维持，包括患者样本量（>150：OS 的 HR=1.77，DFS 的 HR=0.91；或<150：OS 的 HR=1.93，DFS 的 HR=4.39）、种族（亚洲：OS 的 HR=1.65，DFS 的 HR=1.08；或非亚洲：OS 的 HR=3.55，DFS 的 HR=2.87）、数据来源（临床：OS 的 HR=1.24，DFS 的 HR=1.40；或数据库：OS 的 HR=2.29，DFS 的 HR=3.09）、文章发表年份（2014 年后：OS 的 HR=1.90，DFS 的 HR=1.87；或 2014 年前：OS 的 HR=1.40，DFS 的 HR=1.22）、癌症类型（女性特异性癌症：OS 的 HR=1.41，DFS 的 HR=0.64；或非性别特异性癌症：OS 的 HR=2.00，DFS 的 HR=2.95）。此外，根据数据库数据，我们还发现，E2F1 水平升高与患者预后不良相关，且结果与论文中的统计分析结果一致。
E2F1 可作为癌症患者的预后生物标志物，癌症患者中 E2F1 水平升高可预测总体生存期和无病生存期更短。
